Biotech Values

[DewDiligence]

During investor meeting last Jan, Teva's CFO Eyal Deshe talked about Brazil, Russia, Mexico, and Turkey as global targets for Teva and mentioned India and China as the less interesting…

It’s not surprising that Teva would say that because Teva is a minor player in those two countries and has almost no presence in China. SNY, on the other hand, says China is the most interesting emerging market and it has a large presence there. Everyone likes to talk book :- )